Last $1.66 USD
Change Today -0.05 / -2.92%
Volume 530.6K
ARQL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (ARQL) Snapshot

Open
$1.69
Previous Close
$1.71
Day High
$1.75
Day Low
$1.62
52 Week High
04/25/13 - $3.10
52 Week Low
04/17/14 - $1.62
Market Cap
103.6M
Average Volume 10 Days
409.6K
EPS TTM
$-0.39
Shares Outstanding
62.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARQULE INC (ARQL)

arqule inc (ARQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (ARQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover therapeutic compounds that selectively inhibit certain kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

63 Employees
Last Reported Date: 03/5/14
Founded in 1993

arqule inc (ARQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Chief Operating Officer, Principal...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $380.3K
Compensation as of Fiscal Year 2013.

arqule inc (ARQL) Key Developments

ArQule Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 11:20 AM

ArQule Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 11:20 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

ArQule Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Full Year 2014

ArQule Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, research and development revenue was $2,275,000 against $5,143,000 a year ago. Loss from operations was $6,170,000 against $5,455,000 a year ago. Net loss was $5,956,000 or $0.10 per basic and diluted share against $5,296,000 or $0.09 per basic and diluted share a year ago. For the full year, research and development revenue was $15,914,000 against $36,414,000 a year ago. The $20.5 million revenue decrease in 2013 was primarily due to revenue decreases of $15.5 million from its Daiichi Sankyo AKIP agreement that ended in November 2012, $1.5 million from its Daiichi Sankyo ARQ 092 agreement that ended in June 2013 and $5.2 million from its Daiichi Sankyo tivantinib program. These decreases were partially offset by $1.7 million of other revenue related to a one-time research project. Loss from operations was $25,127,000 against $11,404,000 a year ago. Net loss was $24,600,000 or $0.39 per basic and diluted share against $10,872,000 or $0.18 per basic and diluted share a year ago. For the full year of 2014, the company expects net use of cash to range between $35 and $38 million. Revenues are expected to range between $8 and $10 million. Net loss is expected to range between $30 and $33 million, and net loss per share to range between $0.48 and $0.52 for the year. The company expects to end 2014 with between $57 and $60 million in cash and marketable securities.

ArQule Inc. to Report Q4, 2013 Results on Mar 05, 2014

ArQule Inc. announced that they will report Q4, 2013 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARQL:US $1.66 USD -0.05

ARQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.34 USD -0.05
CrystalGenomics Inc 13,450 KRW +250.00
Curis Inc $2.29 USD -0.01
Cytokinetics Inc $9.52 USD +0.45
Rigel Pharmaceuticals Inc $3.20 USD 0.00
View Industry Companies
 

Industry Analysis

ARQL

Industry Average

Valuation ARQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit www.arqule.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.